DSI Poised and Sociable Fragment Libraries Launched to Boost FBDD

January 20, 2026

Two new Fragment Libraries are designed to remove key synthetic bottlenecks in fragment-based drug discovery and accelerate hit-to-lead progression.

DSI Poised Fragment Library

2,300 synthetically versatile fragments built for rapid chemical elaboration and structure-guided optimization

  • Features fragments containing at least one chemically “poised” bond
  • Ready to be rapidly elaborated using reliable reactions: amide coupling, Suzuki cross-coupling, reductive amination
  • Enables fast analog synthesis, parallel chemistry, SAR exploration and structure-guided hit optimization
  • Inspired by poised chemistry concepts introduced by Diamond Light Source (DSI) and the Structural Genomics Consortium (SGC)

Sociable Fragment Library

2,900 fragments optimized for fragment growing from hits to leads, without synthetic dead ends

  • Provides multiple, well-defined synthetic growth vectors
  • Distinguished by the high commercial availability of close analogs
  • Supports rapid, iterative fragment expansion with minimal synthetic risk
  • Ideal for SAR optimization and challenging medicinal chemistry targets

One of the Industry’s Broadest Fragment Collections

Both new fragment libraries complement our proprietary portfolio of nearly 65,000 in-stock fragments, organized into multiple specialized subsets, from 3D-shaped and Fsp³-enriched fragments to PPI, covalent, fluorinated and natural product-like libraries.

✔ Suitable for cherry-picking and open to preparing custom-tailored sets
✔ Also available are pre-plated assay-ready options.

 

➡️ Contact us at orders@lifechemicals.com for more details and/or special fragment selections. 

 

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. By using our website, you accept our conditions of use of cookies to track data and create content (including advertising) based on your interest. Accept